[1]刘文群.莫西沙星治疗对轻中度慢性阻塞性肺疾病急性加重期患者呼吸困难程度、肺功能的影响[J].医学信息,2026,39(04):158-161.[doi:10.3969/j.issn.1006-1959.2026.04.029]
　LIU Wenqun.Effect of Moxifloxacin on Dyspnea and Pulmonary Function in Patients with Acute Exacerbationof Mild to Moderate Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2026,39(04):158-161.[doi:10.3969/j.issn.1006-1959.2026.04.029]
点击复制

莫西沙星治疗对轻中度慢性阻塞性肺疾病急性加重期患者呼吸困难程度、肺功能的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
39卷
期数:
2026年04期
页码:
158-161
栏目:
临床证据信息
出版日期:
2026-02-15

文章信息/Info

Title:
Effect of Moxifloxacin on Dyspnea and Pulmonary Function in Patients with Acute Exacerbationof Mild to Moderate Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2026）04-0158-04
作者:
刘文群
南昌县中医院药剂科，江西 南昌 330200
Author(s):
LIU Wenqun
Department of Pharmacy, Nanchang County Hospital of Traditional Chinese Medicine, Nanchang 330200, Jiangxi, China
关键词:
莫西沙星; 慢性阻塞性肺疾病; 急性加重期; 肺功能
Keywords:
Moxifloxacin;  Chronic obstructive pulmonary disease;  Acute exacerbation;  Pulmonary function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2026.04.029
文献标志码:
A
摘要:
目的 研究轻中度慢性阻塞性肺疾病（COPD）急性加重期患者应用莫西沙星治疗对其呼吸困难程度、肺功能的影响。方法 共纳入2024年1月-9月我院69例符合轻中度COPD急性加重期诊断标准的患者作为研究对象。采用随机数字表法将患者分为两组：其中常规组34例，予以注射用哌拉西林钠他唑巴坦钠治疗；研究组35例，予以盐酸莫西沙星氯化钠注射液治疗。比较两组临床疗效、呼吸困难程度（mMRC评分）、肺功能指标（FVC、FEV1）、炎性指标（WBC、CRP）、不良反应（消化道症状、头痛、皮疹）发生率。结果 研究组治疗总有效率（94.29%）高于常规组（85.29%）（P＜0.05）；两组治疗后呼吸困难程度（mMRC评分）、肺功能指标（FVC、FEV1）、炎性指标（WBC、CRP）较治疗前改善，且研究组优于常规组（P＜0.05）；研究组不良反应发生率（5.71%）低于常规组（14.71%）（P＜0.05）。结论 莫西沙星治疗轻中度COPD急性加重期患者的效果确切，在减轻呼吸困难程度、改善肺功能、抑制炎症反应、降低不良反应发生率方面具有积极作用。
Abstract:
Objective To study the effect of moxifloxacin on dyspnea and pulmonary function in patients with acute exacerbation of mild to moderate chronic obstructive pulmonary disease (COPD). Methods This study included 69 patients meeting the criteria for acute exacerbation of mild to moderate COPD from our hospital during the period of January to September 2024. Patients were randomized via a random number table, 34 patients assigned to the routine group, which were received piperacillin sodium and tazobactam sodium for injection, while the remaining 35 patients in the study group were treated with moxifloxacin hydrochloride and sodium chloride injection. The clinical efficacy, degree of dyspnea (mMRC score), pulmonary function indexes (FVC, FEV1), inflammatory indexes (WBC, CRP), and incidence of adverse reactions (gastrointestinal symptoms, headache, rash) were compared between the two groups. Results The study group demonstrated a significantly higher total treatment effective rate (94.29%) compared to the routine group (85.29%) (P<0.05). After treatment, the degree of dyspnea (mMRC score), pulmonary function indexes (FVC, FEV1) and inflammatory indexes (WBC, CRP) in the two groups were improved compared with those before treatment, with outcomes in the study group being superior to those in the routine group (P<0.05). The study group demonstrated a significantly lower incidence of adverse reactions (5.71%) compared with the conventional group (14.71%) (P<0.05). Conclusion Moxifloxacin is effective in the treatment of patients with mild to moderate acute exacerbation of COPD. It has a positive effect in reducing the degree of dyspnea, improving pulmonary function, inhibiting inflammatory response and reducing the incidence of adverse reactions.

参考文献/References:

[1]Ritchie AI,Wedzicha JA.Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations[J].Clin Chest Med,2020,41(3):421-438.[2]许红飞,刘艳春,王春鲜.两种呼吸喹诺酮类抗菌药序贯给药治疗老年重症慢性阻塞性肺疾病急性加重的对比研究[J].实用老年医学,2021,35(3):270-273.[3]董健.慢性阻塞性肺疾病患者应用莫西沙星治疗的疗效及预后探究[J].中国社区医师,2020,36(8):21,23.[4]郁云龙,周清,温冰.莫西沙星注射液治疗慢性阻塞性肺疾病急性加重期的疗效及安全性分析[J].中国处方药,2020,18(5):74-75.[5]李洁,霍晓颖,陈葆青,等.丹参注射液联合莫西沙星治疗老年慢阻肺急性发作患者的疗效分析[J].现代生物医学进展,2019,19(13):2502-2505,2433.[6]杨丽娟,梁云,韩志成.莫西沙星与头孢哌酮-舒巴坦对老年慢性阻塞性肺疾病患者急性加重期多重耐药的疗效比较[J].抗感染药学,2019,16(10):1788-1790.[7]胡冬梅,王青梅,徐清芳.慢阻肺急性加重期患者呼吸道感染的病原菌分布及耐药性分析[J].实验与检验医学,2020,38(2):389-391.[8]慢性阻塞性肺疾病急性加重诊治专家组.慢性阻塞性肺疾病急性加重诊治中国专家共识(2023年修订版)[J].国际呼吸杂志,2023,43(2):132-149.[9]Ernst P,Dahl M,Chateau D,et al.Comparative effectiveness of fluoroquinolone antibiotic use in uncomplicated acute exacerbations of COPD:A multi-cohort study[J].Int J Chron Obstruct Pulmon Dis,2022,14:2939-2946.[10]王娟,郭秋野,李艳红.痰热清注射液联合莫西沙星治疗慢性阻塞性肺疾病急性加重期的效果[J].世界中西医结合杂志,2019,14(11):1555-1558.[11]朱际富,曾宪辉,陈明松,等.莫西沙星与左氧氟沙星治疗慢性阻塞性肺疾病急性加重期的临床疗效对比[J].吉林医学,2021,42(4):905-907.[12]Minov J,Stoleski S,Petrova T,et al.Moxifloxacin in the Outpatient Treatment of Moderate Exacerbations of Chronic Obstructive Pulmonary Disease[J].Open Access Maced J Med Sci,2018,6(11):2017-2022.[13]韦鹏,吴丽娟,罗毅沣,等.血清皮质醇及相关炎症因子在慢性阻塞性肺疾病急性加重期患者中表达特征的初步研究[J].右江医学,2022,50(11):807-812.[14]王二雄.慢性阻塞性肺疾病急性加重期呼吸道病毒感染与血清炎症因子的相关性研究[D].延安:延安大学,2021.[15]沈波,张浩,毛爽,等.莫西沙星治疗高龄慢性阻塞性肺疾病急性加重期患者的效果观察[J].实用临床医药杂志,2021,25(1):54-57.[16]任英杰,汪桂青,赵美英,等.BiPAP无创通气联合莫西沙星溶液雾化吸入治疗老年慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的疗效[J].中国老年学杂志,2022,42(21):5226-5228.[17]赵晶晶,李亚楠,于立为,等.噻托溴铵联合莫西沙星治疗轻中度慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2024,39(1):151-156.[18]陈辅萍.美罗培南联合莫西沙星治疗慢性阻塞性肺疾病合并感染性肺炎的观察[J].山西医药杂志,2020,49(07):850-852.[19]曾安津,范天琼.美罗培南联合莫西沙星治疗慢性阻塞性肺疾病并发感染性肺炎的疗效观察[J].中国医药科学,2021,11(10):71-74.[20]刘丘岗,翟展艺,李宁宁,等.莫西沙星雾化吸入对慢性阻塞性肺疾病合并呼吸衰竭患者血气指标及炎症因子的影响[J].现代诊断与治疗,2021,32(15):2404-2405.[21]林钦汉,罗刚,陈军.莫西沙星治疗慢性阻塞性肺疾病急性加重期有创机械通气患者的临床效果观察[J].中国医药,2014,9(7):967-969.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(04):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(04):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
　HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(04):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
[10]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(04):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]

更新日期/Last Update: 1900-01-01